This 50-minute presentation reviews the clinical research on expanded states therapy for substance use disorders: LSD, psilocybin, ketamine, MDMA, and ibogaine for alcohol, tobacco, cocaine, and opioid use
disorders. Each finding is graded by strength of evidence, and none of these substances is FDA approved for a substance use disorder. The presentation sets out the current federal and state legal status of these substances, with attention to New Jersey, along with possible mechanisms, risks and limitations, and the relevance of attachment.
It then presents a clinical continuum of screening, preparation, journey, and integration derived from trial protocols, and closes with the roles available to clinicians who do not administer these substances: harm reduction, integration, and referral to legal pathways. Participants will be able to separate established, preliminary, and early findings; describe the federal and state legal status of psilocybin, MDMA, ketamine, and ibogaine and what is still changing; and outline the continuum and the roles open to them. The session ends with open Q&A, and attendees receive a three-page handout with the evidence map, legal status tables, the continuum, and references.
